Reata Pharmaceuticals, Inc. Class A
(NASDAQ : RETA)

( )
RETA After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
MRKMerck & Co., Inc.
0.16%74.720.6%$885.94m
BMYBristol-Myers Squibb Company
-1.55%44.621.4%$877.06m
PFEPfizer Inc.
-0.10%39.380.9%$827.25m
JNJJohnson & Johnson
-0.49%139.220.7%$818.89m
LLYEli Lilly and Company
0.43%118.001.0%$657.11m
ABBVAbbVie, Inc.
0.01%78.672.2%$418.72m
NVSNovartis AG Sponsored ADR
2.49%77.790.2%$297.67m
AZNAstraZeneca PLC Sponsored ADR
0.08%38.721.3%$254.31m
GSKGlaxoSmithKline plc Sponsored ADR
-0.75%39.920.2%$103.67m
NVONovo Nordisk A/S Sponsored ADR Class B
-0.59%48.380.1%$66.63m
SNYSanofi Sponsored ADR
-0.55%41.480.2%$35.58m
LCILannett Company, Inc.
-0.07%7.2036.7%$7.50m
AKTXAkari Therapeutics Plc Sponsored ADR
3.09%4.001.6%$5.96m
EPIXESSA Pharma Inc
4.46%2.400.1%$0.03m

Company Profile

Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff on September 1, 2002 and is headquartered in Irving, TX.